

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1641
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date and submit a copy.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
/LB/		2006/189794 A1	08-24-2006	Tsuchiya <i>et al.</i>
↓		2006/222643 A1	10/05/2006	Tsunoda <i>et al.</i>
↓		2007/003556 A1	01/04/2007	Tsuchiya <i>et al.</i>
↓		2007/280951 A1	12/06/2007	Kimura <i>et al.</i>
↓		2007/281327 A1	12/06/2007	Nakano <i>et al.</i>
↓		2008/009038 A1	01/10/2008	Ohtomo <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/LB/		EPC	1 396 500 A1	03/10/2004	Kirin Beer Kabushiki Kaisha
↓		WIPO	97/01633 A1	01/16/1997	Immunex Corporation
↓		WIPO	2004/087763 A1	10/14/2004	Chugai Seiyaku Kabushiki
↓		WIPO	00/75191 A2	12/14/2000	Genentech, Inc.
↓		WIPO	01/77342 A1	10/18/2001	Genentech, Inc.
↓		WIPO	2004/081048 A1	09/23/2004	Chugai Seiyaku Kabushiki

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
/LB/		Bodmer <i>et al.</i> , "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," <i>Nat Cell Biol.</i> 2:241-243, 2000.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1641
	Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
/LB/		Buchsbaum <i>et al.</i> , "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," <i>Clin Cancer Res.</i> 9:3731-3741, 2003.
		Casset <i>et al.</i> , "A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design," <i>Biochem Biophys Res Comm.</i> 307:198-205, 2003.
		Chen <i>et al.</i> , "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen," <i>J Mol Biol.</i> 293:865-881, 1999.
		Degli-Esposti <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J Exp Med.</i> 186:1165-1170, 1997.
		De Pascalis <i>et al.</i> , "Grafting of 'Abbreviated' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <i>J Immunol.</i> 169:3076-3084, 2002.
		Emery <i>et al.</i> , "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J Biol Chem.</i> 273:14363-14367, 1998.
		Holm <i>et al.</i> , "Functional Mapping and Single Chain Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1," <i>Mol Immunol.</i> 44:1075-1084, 2007.
		MacCallum <i>et al.</i> , "Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography," <i>J Mol Biol.</i> 262:732-745, 1996.
		Marsters <i>et al.</i> , "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," <i>Curr Biol.</i> 7:1003-1006, 1997.
		Mori <i>et al.</i> , "Human Normal Hepatocytes are Susceptible to Apoptosis Signal Mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death Diff.</i> 11:203-207, 2004. Published online October 24, 2003.
		Pan <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> 276:111-113, 1997.
		Pan <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> 277:815-818, 1997.
		Rudikoff <i>et al.</i> , "Single Amino Acid Substitution Altering Antigen-Binding Specificity," <i>Proc Natl Acad Sci USA</i> 79:1979-1983, 1982.
		Sheridan <i>et al.</i> , "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> 277:818-821, 1997.
↓		Skolnick and Fetrow, "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," <i>Trends Biotechnol.</i> 18:34-39, 2000.

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/27/2009
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1641
	Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
/LB/		Vajdos <i>et al.</i> , "Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," <i>J Mol Biol.</i> 320:415-428, 2002.
		Walczak <i>et al.</i> , "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, 1997.
		Wiley <i>et al.</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> 3:673-682, 1995.
		Wu <i>et al.</i> , "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," <i>J Mol Biol.</i> 294:151-162, 1999.

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/27/2009
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			